Olaparib (AZD2281)

Name: Olaparib (AZD2281)
Brand: Selleck Chemicals
SKU: S1060
Rating: 5 (453 reviews)

For research use only. Not for use in humans.

Catalog No.S1060 Synonyms: Ku-0059436

453 publications

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Selleck's Olaparib (AZD2281) has been cited by 453 publications

Cancer Discov, 2019, 9(6):722-737

PubMed: 31015319 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2019, 35(3):519-533

PubMed: 30889383 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nature, 2018, 555(7696):387-391

PubMed: 29513652 ( click the link to review the publication )

Nature, 2018, 560(7716):112-116

PubMed: 30022158 ( click the link to review the publication )

Nature, 2018, 560(7716):117-121

PubMed: 30022168 ( click the link to review the publication )

Nat Biotechnol, 2018, 36(1):95-102

PubMed: 29176614 ( click the link to review the publication )

Cell, 2018, 173(4):972-988

PubMed: 29656893 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Genet, 2018, 50(8):1086-1092

PubMed: 30013182 ( click the link to review the publication )

Cancer Discov, 2018, 8(1):74-93

PubMed: 28923912 ( click the link to review the publication )

Cancer Discov, 2018, 8(8):988-1005

PubMed: 29880585 ( click the link to review the publication )

Cancer Cell, 2018, 33(2):202-216

PubMed: 29358035 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):401-416

PubMed: 29533782 ( click the link to review the publication )

Nature, 2017, 549(7673):548-552

PubMed: 28959974 ( click the link to review the publication )

Nature, 2017, 550(7676):360-365

PubMed: 28976962 ( click the link to review the publication )

Cell, 2017, S0092-8674(17)31437-X

PubMed: 29290468 ( click the link to review the publication )

Nat Med, 2016, 22(2):194-201

PubMed: 26779812 ( click the link to review the publication )

Nature, 2015, 528(7582):422-6

PubMed: 26649820 ( click the link to review the publication )

Cell Metab, 2014, 19(6):1034-41

PubMed: 24814482 ( click the link to review the publication )

Science, 2013, 339(6120):700-4

PubMed: 23306437 ( click the link to review the publication )

Nat Methods , 2013, 10(10):981-4

PubMed: 23955771 ( click the link to review the publication )
Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell, 2011, 145(4):529-42

PubMed: 21565612 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-2000

PubMed: 31900275 ( click the link to review the publication )

Cancer Lett, 2020, 469:78-88

PubMed: 31629931 ( click the link to review the publication )

Sci Transl Med, 2019, 11(492)

PubMed: 31092693 ( click the link to review the publication )

Cell Res, 2019, 29(3):233-247

PubMed: 30728452 ( click the link to review the publication )

Nat Microbiol, 2019, 4(11):1872-1884

PubMed: 30988430 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.10.026

PubMed: 31759821 ( click the link to review the publication )

Mol Cell, 2019, 73(4):845-856

PubMed: 30712989 ( click the link to review the publication )

Mol Cell, 2019, 76(3):473-484

PubMed: 31494034 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.09.024

PubMed: 31653568 ( click the link to review the publication )

Mol Cell, 2019, 73(5):885-899

PubMed: 30686591 ( click the link to review the publication )

Mol Cell, 2019, 75(6):1286-1298

PubMed: 31473101 ( click the link to review the publication )

Mol Cell, 2019, 73(2):224-237

PubMed: 30554948 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.10.008

PubMed: 31676232 ( click the link to review the publication )

Mol Cell, 2019, 73(6):1267-1281

PubMed: 30704900 ( click the link to review the publication )

Mol Cell, 2019, 73(4):670-683.e12

PubMed: 30639241 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1307

PubMed: 30898999 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2556

PubMed: 31186408 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4632

PubMed: 31604914 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4363

PubMed: 31554794 ( click the link to review the publication )

J Clin Invest, 2019, 129(3):1211-1228

PubMed: 30589644 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5367

PubMed: 31772167 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5654

PubMed: 31827085 ( click the link to review the publication )
Nat Commun, 2019, 10(1):5296

PubMed: 31757951 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2849

PubMed: 31253762 ( click the link to review the publication )

Nat Commun, 2019, 10(1):241

PubMed: 30651562 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3925

PubMed: 31477700 ( click the link to review the publication )

Nat Commun, 2019, 10(1):65

PubMed: 30622262 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5661

PubMed: 31827092 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5501

PubMed: 31796734 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(11):5634-5647

PubMed: 31006810 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz820

PubMed: 31566235 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(20):10662-10677

PubMed: 31586400 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(20):6127-6140

PubMed: 31409614 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(20):6206-6216

PubMed: 31409613 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(7):e9982

PubMed: 31273933 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2549

PubMed: 31852834 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31439587 ( click the link to review the publication )

Genes Dev, 2019, 33(5-6):333-347

PubMed: 30796017 ( click the link to review the publication )

Genes Dev, 2019, 33(19-20):1397-1415

PubMed: 31467087 ( click the link to review the publication )

Cancer Res, 2019, 79(17):4491-4502

PubMed: 31273064 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-1673

PubMed: 30733193 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2409

PubMed: 31831554 ( click the link to review the publication )

EMBO Rep, 2019, 20(5)

PubMed: 30940648 ( click the link to review the publication )

Cancer Res, 2019, 79(8):2031-2041

PubMed: 30824588 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32670

PubMed: 31495919 ( click the link to review the publication )
Int J Cancer, 2019, 144(7):1685-1696

PubMed: 30478958 ( click the link to review the publication )

Int J Cancer, 2019, 144(5):1092-1103

PubMed: 30152517 ( click the link to review the publication )

Oncogene, 2019, 38(2):180-193

PubMed: 30093630 ( click the link to review the publication )

J Med Chem, 2019, 62(11):5330-5357

PubMed: 31042381 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):90

PubMed: 30786932 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):463

PubMed: 31718704 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31627329 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12841

PubMed: 31663663 ( click the link to review the publication )

Clin Epigenetics, 2019, 11(1):165

PubMed: 31775874 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):600-610

PubMed: 31481733 ( click the link to review the publication )

FASEB J, 2019, 33(6):6778-6788

PubMed: 30807703 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.10.013

PubMed: 31735695 ( click the link to review the publication )

Stem Cells, 2019, 37(1):42-53

PubMed: 30353615 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31534014 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-17-0256

PubMed: 31575654 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-17-0256

PubMed: 31575654 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0242

PubMed: 31534014 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0474

PubMed: 31597711 ( click the link to review the publication )

Transl Res, 2019, 10.1016/j.trsl.2019.10.003

PubMed: 31707040 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(11):2442-2455

PubMed: 31815045 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(3):608-618

PubMed: 30949414 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(2):431-445

PubMed: 30401718 ( click the link to review the publication )
Mol Cancer Res, 2019, 17(1):42-53

PubMed: 30201826 ( click the link to review the publication )

Lung Cancer, 2019, 135:56-65

PubMed: 31447003 ( click the link to review the publication )

Lung Cancer, 2019, 135:56-65

PubMed: 31447003 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(10):1985-1998

PubMed: 31300540 ( click the link to review the publication )

Cancer Sci, 2019, 110(3):1064-1075

PubMed: 30663191 ( click the link to review the publication )

Biochem Pharmacol, 2019, 10.1016/j.bcp.2019.06.022

PubMed: 31251940 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31554189 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31795418 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31554189 ( click the link to review the publication )

Sci Rep, 2019, 9(1):11153

PubMed: 31371750 ( click the link to review the publication )

J Biol Chem, 2019, 294(33):12459-12471

PubMed: 31248990 ( click the link to review the publication )

J Biol Chem, 2019, 294(2):397-404

PubMed: 30478172 ( click the link to review the publication )

Mol Carcinog, 2019, 58(10):1770-1782

PubMed: 31219654 ( click the link to review the publication )

Mol Carcinog, 2019, 58(10):1770-1782

PubMed: 31219654 ( click the link to review the publication )

Breast Cancer Res Treat, 2019, 176(1):109-117

PubMed: 30989461 ( click the link to review the publication )

Mediators Inflamm, 2019, 2019:1656484

PubMed: 31178661 ( click the link to review the publication )

Mediators Inflamm, 2019, 2019:1656484

PubMed: 31178661 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-018-00717-9

PubMed: 30612311 ( click the link to review the publication )

Virology, 2019, 537:254-262

PubMed: 31539774 ( click the link to review the publication )

Prostate, 2019, 79(4):390-402

PubMed: 30520109 ( click the link to review the publication )

Cell Cycle, 2019, 1-14

PubMed: 31238782 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):829

PubMed: 31438892 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 10.1007/s00432-019-03097-6

PubMed: 31786739 ( click the link to review the publication )

Cancer Med, 2019, 10.1002/cam4.2528

PubMed: 31512408 ( click the link to review the publication )
Transl Oncol, 2019, 12(7):871-878

PubMed: 31075528 ( click the link to review the publication )

Oncol Rep, 2019, 41(6):3555-3564

PubMed: 31002368 ( click the link to review the publication )

J Gynecol Oncol, 2019, 30(2):e26

PubMed: 30740957 ( click the link to review the publication )

PLoS One, 2019, 14(10):e0223725

PubMed: 31596905 ( click the link to review the publication )

PLoS One, 2019, 14(11):e0221288

PubMed: 31721781 ( click the link to review the publication )

PLoS One, 2019, 14(8):e0213130

PubMed: 31408463 ( click the link to review the publication )

PLoS One, 2019, 14(8):e0213130

PubMed: 31408463 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 508(2):620-625

PubMed: 30522863 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 10.1016/j.bbrc.2019.11.050

PubMed: 31753490 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 510(4):501-507

PubMed: 30737031 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(4):1098-1101

PubMed: 30277116 ( click the link to review the publication )

Mol Cell Biochem, 2019, 457(1-2):41-49

PubMed: 30993494 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3609-3616

PubMed: 31485633 ( click the link to review the publication )

Mol Med Rep, 2019, 19(1):75-84

PubMed: 30431088 ( click the link to review the publication )

Am J Vet Res, 2019, 80(7):663-669

PubMed: 31246122 ( click the link to review the publication )

Nanomedicine (Lond), 2019, 14(17):2315-2338

PubMed: 31432749 ( click the link to review the publication )

Oncotarget, 2019, 10(28):2722-2737

PubMed: 31105872 ( click the link to review the publication )

Nanomedicine (Lond), 2019, 14(17):2315-2338

PubMed: 31432749 ( click the link to review the publication )

Commun Biol, 2019, 2:335

PubMed: 31508509 ( click the link to review the publication )

NPJ Breast Cancer, 2019, 5:14

PubMed: 30993195 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(17):9132-9143

PubMed: 31329989 ( click the link to review the publication )

Nat Cell Biol, 2018, 20(2):162-174

PubMed: 29335528 ( click the link to review the publication )

Mol Cell, 2018, 71(1):11-24

PubMed: 29937341 ( click the link to review the publication )

Mol Cell, 2018, 72(4):636-649

PubMed: 30293785 ( click the link to review the publication )
Mol Cell, 2018, 71(6):897-910

PubMed: 30122534 ( click the link to review the publication )

Mol Cell, 2018, 72(1):127-139

PubMed: 30244837 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(9):837-840

PubMed: 30013063 ( click the link to review the publication )

J Clin Invest, 2018, 128(7):2951-2965

PubMed: 29649003 ( click the link to review the publication )

J Clin Invest, 2018, 128(7):2951-2965

PubMed: 29649003 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2678

PubMed: 29992957 ( click the link to review the publication )

J Clin Invest, 2018, 128(10):4525-4542

PubMed: 30222135 ( click the link to review the publication )

Nat Commun, 2018, 9(1):697

PubMed: 29449575 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3982

PubMed: 30266942 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1849

PubMed: 29748565 ( click the link to review the publication )

Nat Commun, 2018, 9(1):176

PubMed: 29330466 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2016

PubMed: 29789535 ( click the link to review the publication )

Nat Commun, 2018, 9(1):144

PubMed: 29321523 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(5):2417-2431

PubMed: 29361132 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(2):804-822

PubMed: 29216372 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(18):9537-9549

PubMed: 30137419 ( click the link to review the publication )

J Immunother Cancer, 2018, 6(1):133

PubMed: 30486888 ( click the link to review the publication )

J Immunother Cancer, 2018, 6(1):133

PubMed: 30486888 ( click the link to review the publication )

Cell Rep, 2018, 24(13):3393-3403

PubMed: 30257201 ( click the link to review the publication )

Cell Rep, 2018, 25(8):2061-2069

PubMed: 30463005 ( click the link to review the publication )

Cell Rep, 2018, 25(8):2061-2069

PubMed: 30463005 ( click the link to review the publication )

Cell Rep, 2018, 23(11):3127-3136

PubMed: 29898385 ( click the link to review the publication )

Cell Rep, 2018, 24(10):2629-2642

PubMed: 30184498 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.37818

PubMed: 30088474 ( click the link to review the publication )
Elife, 2018, 10.7554/eLife.38771

PubMed: 29985131 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 30088474 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.29747

PubMed: 29313488 ( click the link to review the publication )

Cancer Lett, 2018, 423:60-70

PubMed: 29526801 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):129

PubMed: 29954437 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):129

PubMed: 29954437 ( click the link to review the publication )

Cancers (Basel), 2018, 10(5)

PubMed: 29783721 ( click the link to review the publication )

Cancers (Basel), 2018, 10(5)

PubMed: 29783721 ( click the link to review the publication )

PLoS Pathog, 2018, 14(11):e1007394

PubMed: 30395643 ( click the link to review the publication )

Br J Cancer, 2018, 119(11):1392-1400

PubMed: 30425352 ( click the link to review the publication )

Arch Toxicol, 2018, 92(2):759-775

PubMed: 28975372 ( click the link to review the publication )

Arch Toxicol, 2018, 92(2):759-775

PubMed: 28975372 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(6):1167-1176

PubMed: 29626126 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2206-2216

PubMed: 29970481 ( click the link to review the publication )

Mol Oncol, 2018, 12(4):561-576

PubMed: 29465803 ( click the link to review the publication )

Mol Oncol, 2018, 12(4):561-576

PubMed: 29465803 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):428-438

PubMed: 29222170 ( click the link to review the publication )

Int J Nanomedicine, 2018, 13:8063-8074

PubMed: 30555227 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

Biochem Pharmacol, 2018, 150:24-34

PubMed: 29355504 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(9):1837-1846

PubMed: 30323975 ( click the link to review the publication )

Biomed Pharmacother, 2018, 101:719-728

PubMed: 29524880 ( click the link to review the publication )

J Pharmacol Exp Ther, 2018, 365(1):117-126

PubMed: 29339456 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(9):797-808

PubMed: 29923797 ( click the link to review the publication )
Cancer Biol Ther, 2018, 19(9):797-808

PubMed: 29923797 ( click the link to review the publication )

Cancer Med, 2018, 7(4):1285-1296

PubMed: 29479816 ( click the link to review the publication )

Oncol Rep, 2018, 39(5):2261-2269

PubMed: 29512738 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):479-487

PubMed: 29767248 ( click the link to review the publication )

PLoS One, 2018, 13(3):e0194611

PubMed: 29590171 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207399

PubMed: 30444904 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190717

PubMed: 29298345 ( click the link to review the publication )

PLoS One, 2018, 13(12):e0207934

PubMed: 30543656 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207399

PubMed: 30444904 ( click the link to review the publication )

Head Neck, 2018, 40(8):1676-1684

PubMed: 29570891 ( click the link to review the publication )

Head Neck, 2018, 40(8):1676-1684

PubMed: 29570891 ( click the link to review the publication )

Anal Biochem, 2018, 543:132-139

PubMed: 29247608 ( click the link to review the publication )

SLAS Discov, 2018, 23(6):545-553

PubMed: 29676938 ( click the link to review the publication )

Blood Cells Mol Dis, 2018, 71:23-28

PubMed: 29422232 ( click the link to review the publication )

Oncotarget, 2018, 9(88):35844-35855

PubMed: 30533199 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28456-28473

PubMed: 29983873 ( click the link to review the publication )

Oncotarget, 2018, 9(88):35844-35855

PubMed: 30533199 ( click the link to review the publication )

Oncotarget, 2018, 9(99):37319-37332

PubMed: 30647872 ( click the link to review the publication )

DNA Repair (Amst), 2018, 68:12-24

PubMed: 29807321 ( click the link to review the publication )

Oncotarget, 2018, 9(98):37080-37096

PubMed: 30647846 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Biochem Biophys Rep, 2018, 16:115-121

PubMed: 30417129 ( click the link to review the publication )

RNA Biol, 2018, 15(11):1420-1432

PubMed: 30362859 ( click the link to review the publication )

Sci Transl Med, 2017, 9(375)

PubMed: 28148839 ( click the link to review the publication )
Circ Res, 2017, 120(12):1889-1902

PubMed: 28356339 ( click the link to review the publication )

Blood, 2017, 130(26):2848-2859

PubMed: 29042365 ( click the link to review the publication )

Mol Cell, 2017, 65(5):900-916

PubMed: 28238654 ( click the link to review the publication )

Mol Cell, 2017, 67(3):374-386

PubMed: 28735897 ( click the link to review the publication )

Mol Cell, 2017, 65(5):900-916

PubMed: 28238654 ( click the link to review the publication )

Mol Cell, 2017, 66(5):622-634

PubMed: 28575658 ( click the link to review the publication )

Mol Cell, 2017, 66(5):622-634

PubMed: 28575658 ( click the link to review the publication )

Mol Cell, 2017, 68(2):414-430

PubMed: 29053959 ( click the link to review the publication )

Nat Struct Mol Biol, 2017, 24(11):902-910

PubMed: 28991266 ( click the link to review the publication )

Nat Struct Mol Biol, 2017, 24(9):734-742

PubMed: 28805810 ( click the link to review the publication )

Nat Struct Mol Biol, 2017, 24(9):734-742

PubMed: 28805810 ( click the link to review the publication )

Nat Protoc, 2017, 12(9):1951-1961

PubMed: 28837130 ( click the link to review the publication )

J Clin Invest, 2017, 127(8):3013-3027

PubMed: 28691929 ( click the link to review the publication )

J Clin Invest, 2017, 127(6):2392-2406

PubMed: 28481221 ( click the link to review the publication )

Nat Commun, 2017, 8(1):859

PubMed: 29038466 ( click the link to review the publication )

Nat Commun, 2017, 8:14632

PubMed: 28272405 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(7):3906-3921

PubMed: 28160604 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(18):10614-10633

PubMed: 28977657 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(7):3844-3859

PubMed: 28158503 ( click the link to review the publication )

J Thorac Oncol, 2017, 12(8):1309-1319

PubMed: 28389374 ( click the link to review the publication )

EMBO Mol Med, 2017, 9(10):1398-1414

PubMed: 28729482 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(2):514-522

PubMed: 28034904 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(6):1397-1406

PubMed: 27663600 ( click the link to review the publication )

Genes Dev, 2017, 31(1):46-58

PubMed: 28115467 ( click the link to review the publication )
Genes Dev, 2017, 31(3):318-332

PubMed: 28242626 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.30523

PubMed: 29106372 ( click the link to review the publication )

Oncogene, 2017, 36(33):4682-4691

PubMed: 28394338 ( click the link to review the publication )

Cancer Lett, 2017, 398:1-11

PubMed: 28385602 ( click the link to review the publication )

Cancer Lett, 2017, 386:131-140

PubMed: 27894958 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):63

PubMed: 28482906 ( click the link to review the publication )

Cell Death Dis, 2017, 8(1):e2526

PubMed: 28055012 ( click the link to review the publication )

Cell Death Dis, 2017, 8(1):e2526

PubMed: 28055012 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1934-1941

PubMed: 28522591 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(12):2892-2901

PubMed: 28958991 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0740

PubMed: 28500233 ( click the link to review the publication )

Mol Oncol, 2017, 11(5):470-490

PubMed: 28173629 ( click the link to review the publication )

Oncol Res, 2017, 25(9):1441-1451

PubMed: 28429680 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(1):45-58

PubMed: 27671334 ( click the link to review the publication )

Sci Rep, 2017, 7(1):12876

PubMed: 28993682 ( click the link to review the publication )

Virology, 2017, 507:220-230

PubMed: 28456021 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(9):694-704

PubMed: 28886275 ( click the link to review the publication )

Cell Cycle, 2017, 16(11):1128-1135

PubMed: 28463527 ( click the link to review the publication )

Transl Oncol, 2017, 10(2):190-196

PubMed: 28182994 ( click the link to review the publication )

Oncol Res, 2017, 25(9):1441-1451

PubMed: 28429680 ( click the link to review the publication )

PLoS One, 2017, 12(9):e0184619

PubMed: 28886188 ( click the link to review the publication )

PLoS One, 2017, 12(9):e0184619

PubMed: 28886188 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(11):2705-2716

PubMed: 28394191 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 488(1):211-217

PubMed: 28487110 ( click the link to review the publication )
Int J Med Sci, 2017, 14(12):1292-1300

PubMed: 29104487 ( click the link to review the publication )

Mol Med Rep, 2017, 16(1):208-214

PubMed: 28498459 ( click the link to review the publication )

Mol Med Rep, 2017, 16(1):208-214

PubMed: 28498459 ( click the link to review the publication )

Oncotarget, 2017, 8(53):90662-90673

PubMed: 29207595 ( click the link to review the publication )

Oncotarget, 2017, 8(8):13223-13239

PubMed: 28099939 ( click the link to review the publication )

Tumour Biol, 2017, 39(10):1010428317713390

PubMed: 29064327 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68707-68720

PubMed: 28978150 ( click the link to review the publication )

Oncotarget, 2017, 8(67):111026-111040

PubMed: 29340034 ( click the link to review the publication )

Oncotarget, 2017, 8(53):90842-90851

PubMed: 29207607 ( click the link to review the publication )

Oncotarget, 2017, 8(53):90842-90851

PubMed: 29207607 ( click the link to review the publication )

Oncotarget, 2017, 8(55):94505-94518

PubMed: 29212245 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29963-29975

PubMed: 28415784 ( click the link to review the publication )

Blood Adv, 2017, 1(19):1467-1472

PubMed: 29296788 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103931-103951

PubMed: 29262611 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31815-31829

PubMed: 28415632 ( click the link to review the publication )

Oncotarget, 2017, 8(25):40152-40168

PubMed: 27374179 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(12):1357-1366

PubMed: 27820601 ( click the link to review the publication )

Blood, 2016, 127(1):139-48

PubMed: 26463424 ( click the link to review the publication )

Nat Struct Mol Biol, 2016, 23(7):647-55

PubMed: 27239795 ( click the link to review the publication )

Nat Struct Mol Biol, 2016, 23(7):647-55

PubMed: 27239795 ( click the link to review the publication )

J Clin Invest, 2016, 126(8):2903-18

PubMed: 27454287 ( click the link to review the publication )

Nat Commun, 2016, 7:13837

PubMed: 27958275 ( click the link to review the publication )

Nat Commun, 2016, 7:12425

PubMed: 27498558 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(5):2546-2557

PubMed: 27965414 ( click the link to review the publication )
Nucleic Acids Res, 2016, 44(3):1161-78

PubMed: 26578593 ( click the link to review the publication )

EMBO J, 2016, 35(14):1488-503

PubMed: 27225932 ( click the link to review the publication )

Cancer Res, 2016, 76(9):2778-90

PubMed: 27197267 ( click the link to review the publication )

Theranostics, 2016, 6(11):1821-32

PubMed: 27570553 ( click the link to review the publication )

Cancer Res, 2016, 76(10):3067-77

PubMed: 26980768 ( click the link to review the publication )

Cell Rep, 2016, 17(9):2367-2381

PubMed: 27880910 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.13620

PubMed: 27336789 ( click the link to review the publication )

J Invest Dermatol, 2016, 136(6):1219-1228

PubMed: 26880244 ( click the link to review the publication )

Diabetologia, 2016, 59(11):2360-2368

PubMed: 27539148 ( click the link to review the publication )

Br J Cancer, 2016, 114(7):777-86

PubMed: 26964031 ( click the link to review the publication )

Bioinformatics, 2016, 32(12):i253-i261

PubMed: 27307624 ( click the link to review the publication )

Gynecol Oncol, 2016, 142(2):323-31

PubMed: 27282964 ( click the link to review the publication )

DNA Repair , 2016, 10.1016/j.dnarep.2016.06.001

PubMed: 27373144 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

Analyst, 2016, 141(8):2454-62

PubMed: 26974179 ( click the link to review the publication )

Analyst, 2016, 141(8):2454-62

PubMed: 26974179 ( click the link to review the publication )

Mediators Inflamm, 2016, 2016:1984703

PubMed: 27524861 ( click the link to review the publication )

Cell Cycle, 2016, 15(22):3105-3114

PubMed: 27686740 ( click the link to review the publication )

BMC Cancer, 2016, 16:621

PubMed: 27515310 ( click the link to review the publication )

BMC Cancer, 2016, 16(1):851

PubMed: 27816051 ( click the link to review the publication )

BMC Cancer, 2016, 16(1):725

PubMed: 27613518 ( click the link to review the publication )

BMC Cancer, 2016, 16:550

PubMed: 27465688 ( click the link to review the publication )

Eur J Pharmacol, 2016, 791:444-454

PubMed: 27612628 ( click the link to review the publication )

Eur J Pharmacol, 2016, 791:444-454

PubMed: 27612628 ( click the link to review the publication )
Bioorg Med Chem, 2016, 24(5):1071-8

PubMed: 26833244 ( click the link to review the publication )

Neurochem Res, 2016, 41(7):1516-26

PubMed: 26869042 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0146031

PubMed: 26730949 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(1):234-240

PubMed: 27425251 ( click the link to review the publication )

Anal Biochem, 2016, 503:58-64

PubMed: 27036617 ( click the link to review the publication )

Nucl Med Biol, 2016, 43(12):752-758

PubMed: 27689533 ( click the link to review the publication )

Nucl Med Biol, 2016, 43(12):752-758

PubMed: 27689533 ( click the link to review the publication )

Target Oncol, 2016, 11(5):655-665

PubMed: 27188390 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7701-14

PubMed: 26713604 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13984-4001

PubMed: 26910887 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2016, 95(2):772-81

PubMed: 27020103 ( click the link to review the publication )

Oncotarget, 2016, 7(9):9732-41

PubMed: 26799421 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2016, 19(1):16-23

PubMed: 26805733 ( click the link to review the publication )

Oncotarget, 2016, 7(22):32980-9

PubMed: 27145275 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75551-75560

PubMed: 27705909 ( click the link to review the publication )

Nucleic Acids Res, 2015, 43(14):6934-44

PubMed: 26130715 ( click the link to review the publication )

Mol Cancer, 2015, 14:114

PubMed: 26041471 ( click the link to review the publication )

Nanoscale, 2015, 7(6):2805-11

PubMed: 25584654 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.212

PubMed: 26073085 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.443

PubMed: 25619829 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(11):2560-8

PubMed: 26351319 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2818-30

PubMed: 26438158 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-14-0810

PubMed: 25777962 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(5):1236-46

PubMed: 25777962 ( click the link to review the publication )
Mol Cancer Res, 2015, 13(11):1465-77

PubMed: 26217019 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(10):1389-97

PubMed: 26116172 ( click the link to review the publication )

Front Oncol, 2015, 5:191

PubMed: 26380221 ( click the link to review the publication )

Front Oncol, 2015, 5:191

PubMed: 26380221 ( click the link to review the publication )

J Transl Med, 2015, 13:239

PubMed: 26198537 ( click the link to review the publication )

J Transl Med, 2015, 13:225

PubMed: 26169874 ( click the link to review the publication )

J Transl Med, 2015, 13:233

PubMed: 26183824 ( click the link to review the publication )

Sci Rep, 2015, 5:11465

PubMed: 26095524 ( click the link to review the publication )

Sci Rep, 2015, 5:11465

PubMed: 26095524 ( click the link to review the publication )

Front Microbiol, 2015, 6:878

PubMed: 26379653 ( click the link to review the publication )

Biochem J, 2015, 469(2):189-98

PubMed: 25940138 ( click the link to review the publication )

Int J Oncol, 2015, 47(1):262-8

PubMed: 25975349 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):752-67

PubMed: 26069190 ( click the link to review the publication )

Cell Cycle, 2015, 14(20):3261-9

PubMed: 26317799 ( click the link to review the publication )

Cell Cycle, 2015, 14(20):3248-60

PubMed: 26312527 ( click the link to review the publication )

BMC Cancer, 2015, 15:89

PubMed: 25884663 ( click the link to review the publication )

BMC Cancer, 2015, 15(1):1090

PubMed: 25777417 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:3183-90

PubMed: 26124641 ( click the link to review the publication )

Dis Esophagus, 2015, 10.1111/dote.12299

PubMed: 25604309 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 460(2):183-90

PubMed: 25767076 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:3047-54

PubMed: 26543375 ( click the link to review the publication )

Mol Cell Biochem, 2015, 400(1-2):153-62

PubMed: 25404465 ( click the link to review the publication )

J Breast Cancer, 2015, 18(4):329-38

PubMed: 26770239 ( click the link to review the publication )

Oncol Lett, 2015, 9(2):757-761

PubMed: 25621047 ( click the link to review the publication )
Oncotarget, 2015, 6(38):41307-23

PubMed: 26513298 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43679-97

PubMed: 26544897 ( click the link to review the publication )

Oncotarget, 2015, 6(38):41307-23

PubMed: 26513298 ( click the link to review the publication )

DNA Repair (Amst), 2015, 35:106-15

PubMed: 26519824 ( click the link to review the publication )

DNA Repair (Amst), 2015, 26:23-9

PubMed: 25541391 ( click the link to review the publication )

Princeton University, 2015, 88435/dsp01br86b5821

PubMed: ( click the link to review the publication )

Cell, 2015, 161(7):1592-605

PubMed: 26052046 ( click the link to review the publication )

Sci Transl Med, 2014, 6(222):222ra18

PubMed: 24500406 ( click the link to review the publication )

Nat Commun, 2014, 5:5496

PubMed: 25400221 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

Nat Commun, 2014, 5:3946

PubMed: 24867710 ( click the link to review the publication )

Nat Commun, 2014, 5:5496

PubMed: 25400221 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(11):7028-38

PubMed: 24861619 ( click the link to review the publication )

Cancer Res, 2014, 74(21):5948-54

PubMed: 25145669 ( click the link to review the publication )

Cell Rep, 2014, 8(6):1808-18

PubMed: 25199834 ( click the link to review the publication )

Cell Death Differ, 2014, 21(2):258-69

PubMed: 24121277 ( click the link to review the publication )

Eur J Cancer, 2014, 50(15):2725-34

PubMed: 25128455 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):20-8

PubMed: 24534203 ( click the link to review the publication )

Sci Signal, 2014, 7(326):ra47

PubMed: 24847116 ( click the link to review the publication )

J Med Chem, 2014, 57(13):5579-601

PubMed: 24922587 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(2):R25

PubMed: 24625110 ( click the link to review the publication )

J Cereb Blood Flow Metab, 2014, 127(23):5079-92

PubMed: 25248836 ( click the link to review the publication )

J Neuroscience, 2014, 34(28):9338-50

PubMed: 25009267 ( click the link to review the publication )

Arch Toxicol, 2014, 10.1007/s00204-014-1434-0

PubMed: 25526924 ( click the link to review the publication )
PLoS Genet, 2014, 10(10):e1004654

PubMed: 25275444 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(6):1645-54

PubMed: 24694947 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(3):724-32

PubMed: 24356817 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(6):1645-54

PubMed: 24694947 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):986-95

PubMed: 24552776 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.07.022

PubMed: 25139258 ( click the link to review the publication )

Mol Oncol, 2014, S1574-7891(14)00132-X

PubMed: 25028150 ( click the link to review the publication )

Radiother Oncol, 2014, 113(3):345-51

PubMed: 25467050 ( click the link to review the publication )

Oral Oncol, 2014, 50(9):825-31

PubMed: 25017803 ( click the link to review the publication )

Cancer Sci, 2014, 105(2):202-10

PubMed: 24219164 ( click the link to review the publication )

J Cell Mol Med, 2014, 18(1):143-55

PubMed: 24238094 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1852(3):462-472

PubMed: 25483710 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(11):2662-2673

PubMed: 25072752 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1844(10):1765-72

PubMed: 25062913 ( click the link to review the publication )

J Trans Med, 2014, 12(1):184

PubMed: 24965603 ( click the link to review the publication )

Mol Pharmacol, 2014, 9(4):e95649

PubMed: 24748377 ( click the link to review the publication )

Int J Oncol, 2014, 44(3):735-44

PubMed: 24378347 ( click the link to review the publication )

Cell Cycle, 2014, 13(11):1708-16

PubMed: 24675890 ( click the link to review the publication )

Cell Cycle, 2014, 12(11):1679-87

PubMed: 23656790 ( click the link to review the publication )

J Pharm Sci, 2014, 103(6):1913-20

PubMed: 24700236 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108731

PubMed: 25264618 ( click the link to review the publication )

J Cardiovasc Pharmacol, 2014, 10.1038/onc.2014.105

PubMed: 24769898 ( click the link to review the publication )

Medicine, 2014, 93(28):e294

PubMed: 25526472 ( click the link to review the publication )

Oncol Lett, 2014, 8(3):1222-1228

PubMed: 25120693 ( click the link to review the publication )
Oncotarget, 2014, 5(10):3023-8

PubMed: 24632590 ( click the link to review the publication )

Oncotarget, 2014, 5(10):3023-8

PubMed: 24632590 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):347-54

PubMed: 23396353 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(22):10268-82

PubMed: 23997120 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5003-15

PubMed: 23881923 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 12(7):529-34

PubMed: 23684799 ( click the link to review the publication )

Cancer Res, 2013, 72(11):2814-21

PubMed: 22447567 ( click the link to review the publication )

Cancer Res, 2013, 74(1):287-97

PubMed: 24240700 ( click the link to review the publication )

Oncogene, 2013, 32(47):5377-87

PubMed: 23934192 ( click the link to review the publication )

Cancer Lett, 2013, 343(2):217-23

PubMed: 24215868 ( click the link to review the publication )

J Exp Clin Cancer Res, 2013, 32(1):95

PubMed: 24252502 ( click the link to review the publication )

FASEB J, 2013, 27(6):2316-27

PubMed: 23444429 ( click the link to review the publication )

PLoS Genet, 2013, 9(6):e1003531

PubMed: 23785295 ( click the link to review the publication )

Mol Oncol, 2013, 7(3):567-79

PubMed: 23415752 ( click the link to review the publication )

Carcinogenesis, 2013, 34(4):739-49

PubMed: 23275151 ( click the link to review the publication )

Neoplasia, 2013, 15(6):600-8

PubMed: 23730208 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1179-92

PubMed: 23913164 ( click the link to review the publication )

DNA Repair , 2013, 12(12):1134-42

PubMed: 24210699 ( click the link to review the publication )

J Viral Hepat, 2013, 20(9):658-65

PubMed: 23910651 ( click the link to review the publication )

J Biol Chem, 2013, 288(10):7086-95

PubMed: 23355489 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(6):537-45

PubMed: 23760496 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66130

PubMed: 23762475 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66130

PubMed: 23762475 ( click the link to review the publication )

J Mass Spectrom, 2013, 48(12):1285-90

PubMed: 24338883 ( click the link to review the publication )
DNA Repair (Amst), 2013, 12(6):394-402

PubMed: 23570906 ( click the link to review the publication )

Hepatology, 2012, 55(6):1840-51

PubMed: 22223166 ( click the link to review the publication )

Nat Struct Mol Biol, 2012, 19(4):417-23

PubMed: 22388737 ( click the link to review the publication )

EMBO Mol Med, 2012, 4(10):1087-96

PubMed: 22933245 ( click the link to review the publication )

Oncogene, 2012, 32(39):4634-45

PubMed: 23108394 ( click the link to review the publication )

Cancer Lett, 2012, 319(2):232-41

PubMed: 22266096 ( click the link to review the publication )

J Med Chem, 2012, 55(7):3011-20

PubMed: 22380680 ( click the link to review the publication )

PLoS Genet, 2012, 8(3):e1002574

PubMed: 22412391 ( click the link to review the publication )

Neoplasia, 2012, 14(3):169-77

PubMed: 22496617 ( click the link to review the publication )

DNA Repair , 2012, 11(6):537-49

PubMed: 22542292 ( click the link to review the publication )

Cancer Sci, 2012, 103(6):1045-50

PubMed: 22404155 ( click the link to review the publication )

J Biol Chem, 2012, 287(47):39824-33

PubMed: 21956491 ( click the link to review the publication )

J Biol Chem, 2012, 287(44):36777-91

PubMed: 22961983 ( click the link to review the publication )

J Biol Chem, 2012, 287(52):43720-9

PubMed: 23105099 ( click the link to review the publication )

PLoS One, 2012, 7(6):e39956

PubMed: 22768182 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2012, 84(3):815-21

PubMed: 22417805 ( click the link to review the publication )

ACS Nano, 2011, 5(11):9216-24

PubMed: 21962084 ( click the link to review the publication )

J Biol Chem, 2011, 286(14):12157-65

PubMed: 21285347 ( click the link to review the publication )

Mol Cell Biol, 2011, 31(12):2462-9

PubMed: 21482670 ( click the link to review the publication )

PLoS One, 2011, 6(11):e27183

PubMed: 22073281 ( click the link to review the publication )

EMBO Rep, 2010, 11(12):962-8

PubMed: 21052091 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Features

A potent PARP inhibitor (currently in late stage clinical trials).

Targets

PARP2 ^[1] (Cell-free assay)	PARP1 ^[1] (Cell-free assay)
1 nM	5 nM

In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). ^[1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KP3.33	M1:zTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mm\6OEBl		NHza[4JKSzVyPUWuO\|A2KCEQvF2g	MoW0NVg2PTl4MUO=
KP6.3	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH:1Vm81KGR?		M3juXWlEPTB;MUCuOFI5KM7:TTC=	NGrZVGoyQDV3OU[xNy=>
KP7.7	MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXy0JIQ>		MUDJR\|UxRTV5IH7NJC=>	NG\2cVgyQDV3OU[xNy=>
KB2P3.4	NYjUcXdRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXK0JIQ>		MX7JR\|UxRTF{NDDNJC=>	NULkNFM4OTh3NUm2NVM>
KB2P1.21	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MY[0JIQ>		NUDEWnpsUUN3ME24PVA4KG6PIB?=	MoCwNVg2PTl4MUO=
U373-MG	NHHafWREgXSxdH;4bYMhSXO\|YYm=	MVGxJO69VSB?	MoKxNlQhcA>?		NYLBZlBSUW6lcnXhd4V{KHKjZHnheIlwdiC\|ZX7zbZRqfmm2eR?=	MUixPFk2PDdzMh?=
T98G	MmrxR5l1d3SxeHnjJGF{e2G7	M3KyRVEh\|ryPIB?=	NGDqb3UzPCCq		MVLJcoNz\WG\|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6	M3niRVE5QTV2N{Gy
U87-MG	NILMOGxEgXSxdH;4bYMhSXO\|YYm=	NXL6fJpmOSEQvF2g	MWiyOEBp		MX\JcoNz\WG\|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6	NYGz[Gt[OTh7NUS3NVI>
UVW	M{XxdmN6fG:2b4jpZ{BCe3OjeR?=	MUW1NFAhdk1?	M{nuRlI1KGh?		M1yzW2lv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl?	M3SxWVE5QTV2N{Gy
HeLa	M3rj[mZ2dmO2aX;uJGF{e2G7	Ml3LOVAxKG6P	NIrIV2I1KGh?		NXvo[VgyS2G3c3XzJIEhdW:mZYP0JIRmdGG7IHnuJJJmcm:rbnnu[{Bw\iC{YXTpZZRqd25vaX7keYNm\CCGTlGgZpJm[Wu\|	NHzYZW0yQDl3NEexNi=>
HeLa	NWrib3RxTnWwY4Tpc44hSXO\|YYm=	M1TCPVEh\|ryPIB?=	MlfXNlQhcA>?		M{K2cGVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJHMueGijc3WgZZJz\XO2	MmrCNVg6PTR5MUK=
T98G	MXHGeY5kfGmxbjDBd5NigQ>?	NFO1XWoyKM7:TTC=	NXv2XZJvOjRiaB?=		MYXFcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDTMZBp[XOnIHHydoV{fA>?	NXrDdGVsOTh7NUS3NVI>
L3	MmLtR5l1d3SxeHnjJGF{e2G7	NUTS[m1jPSEQvF2g	MUi5OkBp	M{PPOGROW09?	MV3TbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHygd5Vzfmm4YXy=	MmnVNlAyOjR2NUm=
Granta-519	NVvZd4V4S3m2b4TvfIlkKEG\|c3H5	M4TWW\|Uh\|ryPIB?=	M{DoNlk3KGh?	MYrEUXNQ	NELTdJZUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu	M1WyXFIxOTJ2NEW5
BT	NXr1WWliS3m2b4TvfIlkKEG\|c3H5	NED1OWM2KM7:TTC=	NXS0eY4yQTZiaB?=	NWi2bnlnTE2VTx?=	MV\TcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt	NEDNe\|QzODF{NES1PS=>
UPN2	MorqR5l1d3SxeHnjJGF{e2G7	NHPwfHo2KM7:TTC=	MYW5OkBp	NYDL[pZsTE2VTx?=	M37ZN3NtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx?	MkXuNlAyOjR2NUm=
HBL-2	M{nIeWN6fG:2b4jpZ{BCe3OjeR?=	MUW1JO69VSB?	NX;rSo9QQTZiaB?=	NFvzbGdFVVOR	M4T2PHNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx?	M37uXlIxOTJ2NEW5
JVM-2	NVHD[otDS3m2b4TvfIlkKEG\|c3H5	NWn0OpA4PSEQvF2g	M{DqbVk3KGh?	NGHtS\|lFVVOR	MmfrV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC\|dYL2bZZidA>?	M2XS[VIxOTJ2NEW5
Z138	MW\DfZRwfG:6aXOgRZN{[Xl?	M4\nR\|Uh\|ryPIB?=	M{HhSFk3KGh?	NXPOXY9RTE2VTx?=	M1rNW3NtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx?	M3\icVIxOTJ2NEW5
RWPE	MnqyTY53[XOrdnWgRZN{[Xl?	MlnTNlUh\|ryP	M2fXXFQ5KGh?	M3K5RWROW09?	M3[4S3Nq\26rZnnjZY51dHlicnXkeYNmeyCHUlet[JJqfmWwIHPlcIwhcW64YYPpc44>	NXHsNoZwOjF3N{W4OlU>
VCaP	MmC0TY53[XOrdnWgRZN{[Xl?	M{LNW\|I2KM7:TR?=	M4nuelQ5KGh?	MkTmSG1UVw>?	M2O2fnNq\26rZnnjZY51dHlicnXkeYNmeyCHUlet[JJqfmWwIHPlcIwhcW64YYPpc44>	NYPwcndPOjF3N{W4OlU>
Mouse H2AX−/− ES Cells	NH3iNG9EgXSxdH;4bYMhSXO\|YYm=	MWSyMlUh\|ryP	NFvDNGozOCCq		MlPrV4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs	NUPHZYlFOjN\|NUW0PFk>
Mouse ATM−/− ES Cells	NGHr[GdEgXSxdH;4bYMhSXO\|YYm=	NWDxeGdwOi53IN88US=>	M3WzbFIxKGh?		MVTTbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHygd5Vzfmm4YXy=	MW[yN\|M2PTR6OR?=
H1650	MnnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYeyNEDPxE1?	MlPyNVQ1KGh?		M2nFZmlEPTB;MUWuOFch\|ryP	MVuyN\|I{QThyOR?=
H1650PTEN+	MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;wdlIxKM7:TR?=	MYSxOFQhcA>?		MmTVTWM2OD13MD64N{DPxE1?	M3\SN\|I{OjN7OEC5
PC-9	NYThc2k6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWOyNEDPxE1?	MonVNVQ1KGh?		MkP6TWM2OD13Lki4JO69VQ>?	NHWxSVYzOzJ\|OUiwPS=>
PC-9PTEN−	NGLkSpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2CxeVIxKM7:TR?=	MYixOFQhcA>?		NGnMfGpKSzVyPU[uOVIh\|ryP	M1PGWlI{OjN7OEC5
MDA-MB-231	M{PnUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NV3lTI54PSCmYYm=		NFftN5hKSzVyPU[uPUDPxE1?	MnTrNlM4PjB2OU[=
MDA-MB-468	NVjtTFZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXK1JIRigQ>?		MUTJR\|UxRTVwMDFOwG0>	MXWyN\|c3ODR7Nh?=
BT20	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{PnZlUh\GG7		NGS5UohKSzVyPUeuO{DPxE1?	NXnMOHhlOjN5NkC0PVY>
HCC1143	NH\he\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYK1JIRigQ>?		MYHJR\|UxRTFzLkGg{txO	M4jZfVI{PzZyNEm2
HCC1937	NYLBfIlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3PQNVUh\GG7		NGDMOnBKSzVyPUGyMlYh\|ryP	NFvqV3ozOzd4MES5Oi=>
Hs578t	NH:zbVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkTBOUBl[Xl?		MWXJR\|UxRTVwNjFOwG0>	NHHaT3czOzd4MES5Oi=>
Hs578t(si)	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXG1JIRigQ>?		NYTHT3RpUUN3ME23MlUh\|ryP	MnTNNlM4PjB2OU[=
BT474	NVrTXG9nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3r3VFUh\GG7		Mki5TWM2OD1zOT64JO69VQ>?	Ml7yNlM4PjB2OU[=
JIMT1	M{LrNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV:1JIRigQ>?		MlPVTWM2OD15Lkeg{txO	MnTwNlM4PjB2OU[=
SKBR3	M3rSeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIj2dIs2KGSjeR?=		MWfJR\|UxRTFzLkGg{txO	MU[yN\|c3ODR7Nh?=
SUM159	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWK1JIRigQ>?		Ml6zTWM2OD12LkKg{txO	NFfvd20zOzd4MES5Oi=>
CAMA1	Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn64OUBl[Xl?		Mkn2TWM2OD1zNT64JO69VQ>?	NX[4cHVzOjN5NkC0PVY>
MCF7	NELVXHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYW1JIRigQ>?		NEnEbXJKSzVyPUWuPEDPxE1?	M3ryflI{PzZyNEm2
T47D	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3jyWFUh\GG7		NIq3[GJKSzVyPUmuOkDPxE1?	MmfyNlM4PjB2OU[=
HCT116	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;Ccot7OTByIN88US=>	MWO0PEBp	NIjubFlFVVOR	NU\q[mRnUUN3ME2yMlUh\|ryPIB?=	NVHpTWpYOjR3N{e5OFE>
SW1116	NX3FU2hTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{K3S\|ExOCEQvF2=	NVe2Omk1PDhiaB?=	MnrQSG1UVw>?	M{e1RWlEPTB;MUCwJO69VQ>?	MXyyOFU4Pzl2MR?=
HT29	NE\BVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzUO48yODBizszN	MnH4OFghcA>?	MWrEUXNQ	M1fzS2lEPTB;MUSuO{DPxE1?	MnPKNlQ2Pzd7NEG=
LoVo	NXrOW4tIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHO4NHUyODBizszN	NGnrd441QCCq	NWDoOFh{TE2VTx?=	NYLzWVVNUUN3ME2xN{41KM7:TR?=	NVTydWdjOjR3N{e5OFE>
HCT-15	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX[xNFAh\|ryP	NIHMR2o1QCCq	NUXpPVIyTE2VTx?=	M13BbmlEPTB;MUCg{txO	MoqyNlQ2Pzd7NEG=
SW48	MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4C0PFExOCEQvF2=	NFHt[mU1QCCq	NYjPRpN2TE2VTx?=	NGi3dmFKSzVyPUmuOUDPxE1?	MlXPNlQ2Pzd7NEG=
C-1	MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYKxNFAh\|ryP	MlzwOFghcA>?	MWrEUXNQ	Moi4TWM2OD15Lk[g{txO	NW\5fYFvOjR3N{e5OFE>
RKO	MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3UXIl1OTByIN88US=>	NIHQO4U1QCCq	NHixe\|ZFVVOR	M2jXWGlEPTB;NT65JO69VQ>?	MkLBNlQ2Pzd7NEG=
HCT116	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrCOI8xOTByIN88US=>	MXq0PEBp	MXfEUXNQ	MXPQc5RmdnSrYYTld{BUVi1\|ODDjfZRwfG:6aXPpeJkh	M4P4TVI1PTd5OUSx
SW1116	NVXSN4Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTp[3l2OTByIN88US=>	MUO0PEBp	NH\YOY5FVVOR	MXXQc5RmdnSrYYTld{BUVi1\|ODDjfZRwfG:6aXPpeJkh	NYLTPGZGOjR3N{e5OFE>
HT29	MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXGxNFAh\|ryP	NYnPTmdiPDhiaB?=	NG\PT3NFVVOR	NYPDR4I2WG:2ZX70bYF1\XNiU16tN\|gh[3m2b4TvfIlkcXS7IB?=	Mo\INlQ2Pzd7NEG=
LoVo	NH21e4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mkn5NVAxKM7:TR?=	MX:0PEBp	NF7HfJBFVVOR	M1fVd3BwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB?	M33ibFI1PTd5OUSx
SW48	MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvkWJNyOTByIN88US=>	NGTwVFE1QCCq	MXvEUXNQ	MlTGVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>?	NYXWOpJSOjR3N{e5OFE>
C-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUSyW5lxOTByIN88US=>	Mle4OFghcA>?	M2jkfWROW09?	NHL6NmlRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli	MmnyNlQ2Pzd7NEG=
RKO	M{fERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVixNFAh\|ryP	M4[wS\|Q5KGh?	MYDEUXNQ	MkjsVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>?	MXSyOFU4Pzl2MR?=
HCT116	NGn3OnRHfW6ldHnvckBCe3OjeR?=	Mk\4NVAhdk1?	NIjBNZgyOiCq	MVvEUXNQ	MWjJcoNz\WG\|ZYOgSG5CKGSxdXLs[U1{fHKjbnSgZpJm[Wu\|IHnu[JVk\WRiYomgV24uOzh?	M1jxWVI1PTd5OUSx
HT29	MXnGeY5kfGmxbjDBd5NigQ>?	NE\EUGEyOCCwTR?=	NHHldGUyOiCq	Ml7vSG1UVw>?	MV;JcoNz\WG\|ZYOgSG5CKGSxdXLs[U1{fHKjbnSgZpJm[Wu\|IHnu[JVk\WRiYomgV24uOzh?	MWSyOFU4Pzl2MR?=
TE-6	MVHGeY5kfGmxbjDBd5NigQ>?	NEn6fm42KM7:TTC=	NEXiOHUyOiCq	MUfEUXNQ	NWK5Zo1jUW6mdXPld{BIOi:PIHHydoV{fA>?	NXTXVWtSOjR{MUmxOlQ>
TE-6	NYDYOGE3TnWwY4Tpc44hSXO\|YYm=	MnrIOUDPxE1i	M2XGdVI1KGh?	NWDCUmduTE2VTx?=	M4XXcGlv[3KnYYPld{BqdiCmb4XicIUhe3S{YX7kJIJz\WGtczCoSHNDeyl?	MUiyOFIyQTF4NB?=
Hep3B	Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M372c\|QxKM7:TTC=	NHf2WHo4OiCq	MVvEUXNQ	NWjEWHBxW3mwZYLnbZN1cWOjbHz5JIlvcGmkaYTzJINmdGxiZ4Lve5RpKHerdHigSGhOTVF?	M{TYXlI2ODd{N{Wy
Huh7	M2m2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXmOFAh\|ryPIB?=	NX\q[mNYPzJiaB?=	MknhSG1UVw>?	M{j6dHN6dmW{Z3nzeIlk[WyueTDpcohq[mm2czDj[YxtKGe{b4f0bEB4cXSqIFTIUWVS	NXL3SnNkOjVyN{K3OVI>
Hep3B	NWrrOGdHTnWwY4Tpc44hSXO\|YYm=	M1nlW\|QxKM7:TTC=	M2\pc\|I1KGh?	MWnEUXNQ	MUPJcoR2[2W\|IGLPV{Bxem:mdXP0bY9vKHerdHigSGhOTVF?	NHnQSHkzPTB5Mke1Ni=>
Huh7	Mm\6SpVv[3Srb36gRZN{[Xl?	NHvpdWU1OCEQvF2g	M4fxRVI1KGh?	MU\EUXNQ	NWO3SlR3UW6mdXPld{BTV1NicILv[JVkfGmxbjD3bZRpKESKTVXR	NXXFXXlQOjVyN{K3OVI>
Hep3B	MYjGeY5kfGmxbjDBd5NigQ>?	NGHxdlI1OCEQvF2g	MmrJNlQhcA>?	M2DNT2ROW09?	Mlu1TY5lfWOnczDj[YxtKGG3dH;wbIFogSC5aYToJGRJVUWT	NWDXeIxKOjVyN{K3OVI>
Huh7	MmDqSpVv[3Srb36gRZN{[Xl?	MVu0NEDPxE1i	NVnHeG9lOjRiaB?=	M1[zVGROW09?	MmfNTY5lfWOnczDj[YxtKGG3dH;wbIFogSC5aYToJGRJVUWT	MkfoNlUxPzJ5NUK=
SGC-7901	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVKzNOKh\|ryP	MknQOFghcA>?	NEHpNJFFVVOR	Mo\JRoxw[2tib4jhcIlxdGG2aX6tbY5lfWOnZDDj[YxtKGSnYYTo	MonONlU4PjdyN{[=
COLO-800	M1W5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XxN2lEPTB;MD60OFE3PCEQvF2=	M{m1PXNCVkeHUh?=
EoL-1-	NYjidIx3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPvPIdKSzVyPUCuOVY1PDZizszN	M3TFU3NCVkeHUh?=
NCI-H209	NV[xdZhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTBwOUG1OVYh\|ryP	NYnYNWdMW0GQR1XS
ES1	MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmW0TWM2OD1zLkGxOFA5KM7:TR?=	NGCwWlBUSU6JRWK=
NKM-1	M2juRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlnWTWM2OD1zLkK1N\|Q4KM7:TR?=	NXH2co9nW0GQR1XS
NTERA-S-cl-D1	Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFS0XFlKSzVyPUGuN\|M{PDFizszN	Mn7EV2FPT0WU
MHH-ES-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXyfoZKSzVyPUGuOlIxPjdizszN	MU\TRW5ITVJ?
ES8	NH3ScmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPVTWM2OD1zLkeyOFE1KM7:TR?=	M4rROXNCVkeHUh?=
NCI-H720	MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPUcHV{UUN3ME2yMlIxPjl7IN88US=>	NY\qbnROW0GQR1XS
EW-3	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jRVWlEPTB;Mj6yO\|U{PCEQvF2=	MoDyV2FPT0WU
D-566MG	NUXINIt{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTJwNES1Olgh\|ryP	M3rNbnNCVkeHUh?=
697	M{O4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrjNZd6UUN3ME2yMlg1OTd\|IN88US=>	NYPGeFdEW0GQR1XS
ES5	NXmxWll3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTJwOEixPFkh\|ryP	MYjTRW5ITVJ?
COLO-684	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnqd2RKSzVyPUOuOVE3QTZizszN	NHK2XZhUSU6JRWK=
ML-2	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjCTlBKSzVyPUOuOlAxPThizszN	NX3YS\|ExW0GQR1XS
MC-IXC	MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTNwNkOzPVMh\|ryP	MmLpV2FPT0WU
DB	NUXrTmo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7JVplKSzVyPUOuOlU1PDhizszN	M4XacHNCVkeHUh?=
HCC2218	M1nUU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTNwN{OxNFMh\|ryP	NYX0d4lpW0GQR1XS
NCI-H510A	MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmj1TWM2OD1\|LkiyO\|I1KM7:TR?=	MkTVV2FPT0WU
NCI-H526	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvuepFiUUN3ME2zMlg3QTV6IN88US=>	MWLTRW5ITVJ?
MV-4-11	NWTENW9HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4Lx[2lEPTB;ND6xN\|M{PCEQvF2=	M4rKbnNCVkeHUh?=
PA-1	NH7mdHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17vbmlEPTB;ND6yOVI6KM7:TR?=	NU\3S4pMW0GQR1XS
EW-22	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLWTW5OUUN3ME20MlM2QDZizszN	NX7Xcot6W0GQR1XS
KASUMI-1	M4nWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;BOmlEPTB;ND60NFExQSEQvF2=	NFHuTppUSU6JRWK=
LU-139	MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLRT\|Q3UUN3ME20Mlc2QDJ7IN88US=>	MWTTRW5ITVJ?
SBC-1	NEnGPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFW3Z\|ZKSzVyPUSuPFA6ODhizszN	M2PiUHNCVkeHUh?=
H4	NEjPblBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HSe2lEPTB;ND64PVQ1OyEQvF2=	MmKwV2FPT0WU
EW-11	M1na[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTVwMEiwO\|Ih\|ryP	M{DsTXNCVkeHUh?=
NBsusSR	Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTVwMUKwOVUh\|ryP	NEfqSINUSU6JRWK=
RPMI-8226	NYTwXXRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TROWlEPTB;NT6xOVI1PCEQvF2=	NEDsV2dUSU6JRWK=
DEL	NXL5ToNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYT3dI43UUN3ME21MlIxODB4IN88US=>	NF;6TpdUSU6JRWK=
ES4	NVPqVVJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvMTWM2OD13LkWxN\|g6KM7:TR?=	Mkj4V2FPT0WU
GCT	NYfkWopnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn74TWM2OD13LkW2PFU3KM7:TR?=	NV;H[\|BGW0GQR1XS
NCI-H1048	Ml\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HnUWlEPTB;NT65O\|I4OyEQvF2=	M2KzcXNCVkeHUh?=
NCI-SNU-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLzXG1KSzVyPU[uNFIzKM7:TR?=	M3Lm[XNCVkeHUh?=
ES7	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnixTWM2OD14LkCzOVc4KM7:TR?=	MXnTRW5ITVJ?
SW982	NFm3SYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTZwMEmxN\|ch\|ryP	NY\WcVVqW0GQR1XS
L-363	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7DTWM2OD14LkOzPVc1KM7:TR?=	NXTuXms2W0GQR1XS
HT-1080	NGLQfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTZwNEm2PFMh\|ryP	NYKyeVQ{W0GQR1XS
HAL-01	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nHOGlEPTB;Nj61NVA6KM7:TR?=	MYTTRW5ITVJ?
NB14	M1vLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTZwNkSwN\|kh\|ryP	MVXTRW5ITVJ?
EW-13	M1j3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLhTWM2OD14Lke3OFI1KM7:TR?=	NHrFS2tUSU6JRWK=
NY	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\QNIQ1UUN3ME22Mlk1PjB3IN88US=>	MXjTRW5ITVJ?
NCI-SNU-5	M13rZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrUSIdoUUN3ME23MlExPDN\|IN88US=>	MXXTRW5ITVJ?
MS-1	NVvC[\|kxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYj4NHJPUUN3ME23MlE4PDl2IN88US=>	MoDhV2FPT0WU
EW-16	NYKyUIlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4raXmlEPTB;Nz6zNVg3OSEQvF2=	NFOzSXRUSU6JRWK=
LU-65	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfYTWM2OD15LkS4OFE4KM7:TR?=	M4PQRnNCVkeHUh?=
HGC-27	NWXxfZBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTdwN{KxO\|Mh\|ryP	M3PUSXNCVkeHUh?=
CTB-1	Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm[4TWM2OD15Lke2NVc2KM7:TR?=	MVHTRW5ITVJ?
5637	MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTdwOUK4OkDPxE1?	Ml3DV2FPT0WU
U251	NXOycmdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDSVWlKSzVyPUeuPVQxOTZizszN	NGm5PXNUSU6JRWK=
HOS	NWHlNG9CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLwTWM2OD16LkKzNFA4KM7:TR?=	NHThbZhUSU6JRWK=
DOHH-2	NUjaWGx3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7FTWM2OD16LkKzOVgh\|ryP	NHridIFUSU6JRWK=
EW-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrOcJNKSzVyPUiuN\|AxQDhizszN	M2iwO3NCVkeHUh?=
BV-173	M4XmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRThwNUW1OEDPxE1?	NVTG[mx1W0GQR1XS
8-MG-BA	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofJTWM2OD16Lk[4PVg5KM7:TR?=	MVLTRW5ITVJ?
NB69	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkT5TWM2OD16LkewPVIyKM7:TR?=	M3\1NHNCVkeHUh?=
NCI-H69	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzlTWM2OD17LkmwPVYyKM7:TR?=	MmSxV2FPT0WU
RS4-11	NW[5eHBJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTFzLkKyNFgh\|ryP	NUnHXnE{W0GQR1XS
ONS-76	M4PwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInXd4NKSzVyPUGxMlI6PDdizszN	NWHJT2NWW0GQR1XS
SF539	MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTFzLkS4PFkh\|ryP	NFT6cYJUSU6JRWK=
HuO-3N1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nPXmlEPTB;MUGuOVc6PiEQvF2=	NVPzdZVYW0GQR1XS
NCI-H1651	NXPsbGdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTF{LkOxNVUh\|ryP	NIHvfIpUSU6JRWK=
KARPAS-45	NF3qU\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;UVmlEPTB;MUKuN\|c3KM7:TR?=	MnroV2FPT0WU
SK-NEP-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHi5clZKSzVyPUGyMlQ3ODlizszN	Mlq4V2FPT0WU
LAMA-84	M4K0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTXPWlKSzVyPUGzMlExQTVizszN	NGTTVHFUSU6JRWK=
NCI-H1155	M2C5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlnzTWM2OD1zMz6yPFU3KM7:TR?=	MV7TRW5ITVJ?
CTV-1	NUnmcIpzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTF\|LkS0OUDPxE1?	MmPiV2FPT0WU
QIMR-WIL	M{XsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTF\|Lke4NVQh\|ryP	M3LTSXNCVkeHUh?=
H9	M1rNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LmTGlEPTB;MUOuPFQ4PSEQvF2=	Ml;LV2FPT0WU
SK-MEL-1	MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULIb5FJUUN3ME2xN{46OzR5IN88US=>	M3GxNXNCVkeHUh?=
HD-MY-Z	NHn1NoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37vRmlEPTB;MUSuNFY{PyEQvF2=	MX;TRW5ITVJ?
TI-73	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\4TWM2OD1zND6yN\|U3KM7:TR?=	NXO1fXp[W0GQR1XS
JVM-3	NEXBR\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkW0TWM2OD1zNT61O\|E3KM7:TR?=	M1HibXNCVkeHUh?=
D-247MG	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTF3LkW5N{DPxE1?	NHq3NIlUSU6JRWK=
VA-ES-BJ	MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjMfG5qUUN3ME2xOU43ODl5IN88US=>	MYXTRW5ITVJ?
NOS-1	NX2zRVVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLyeWhKSzVyPUG1MlY2OjJizszN	NH3JXG1USU6JRWK=
MOLT-4	NIXkXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\sTWM2OD1zNj63OVIh\|ryP	NFHjUXJUSU6JRWK=
Mo-T	M1zVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlT1TWM2OD1zNz6wPFQ6KM7:TR?=	MWLTRW5ITVJ?
NCI-H1770	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvSS25KSzVyPUG3MlE2PDNizszN	NYHmRXJvW0GQR1XS
COLO-320-HSR	M1\p[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfyZ45KSzVyPUG3MlE5OjdizszN	MXvTRW5ITVJ?
TE-12	Ml61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPPTWM2OD1zNz63NFU1KM7:TR?=	MkPPV2FPT0WU
NCI-H82	NXWyZ\|g1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LsdGlEPTB;MUeuPFczQCEQvF2=	M{LVVnNCVkeHUh?=
NEC8	M{nwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHUS3ZKSzVyPUG4MlE{OTZizszN	NUXDSGhRW0GQR1XS
HSC-3	MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGK1XllKSzVyPUG4Mlc1OTRizszN	M{DDUXNCVkeHUh?=
NCI-H1092	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTF6Lke1PVUh\|ryP	NEjNbXFUSU6JRWK=
NCI-H292	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XONGlEPTB;MUmuNFQ5QSEQvF2=	NETqdVVUSU6JRWK=
L-428	NV2yPGlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVy3foN[UUN3ME2xPU42PTlizszN	MlnYV2FPT0WU
LU-134-A	NXnzNm9OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonNTWM2OD1zOT61O\|Ih\|ryP	M{Tse3NCVkeHUh?=
GI-ME-N	NXvMdoF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4qzfWlEPTB;MUmuOVc1PyEQvF2=	MVrTRW5ITVJ?
ALL-PO	NITWUmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1e5d2lEPTB;MUmuOVk4OiEQvF2=	NH7UNWpUSU6JRWK=
D-283MED	NInrWGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrnW2ZKSzVyPUG5MlkyPSEQvF2=	NULFWVRxW0GQR1XS
D-423MG	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnTTWM2OD1zOT65PVY4KM7:TR?=	NX;DT3lKW0GQR1XS
CAKI-1	NF7MOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjkTWM2OD1{MD6yNlE6KM7:TR?=	NHzPRXNUSU6JRWK=
ETK-1	NGTVeIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYOxbWlLUUN3ME2yNE4zPjF3IN88US=>	NX\GVlYxW0GQR1XS
G-402	NYDFOHIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13zPGlEPTB;MkCuOVM{PCEQvF2=	M2nxSnNCVkeHUh?=
HL-60	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTJzLkG2NVMh\|ryP	M3HGfHNCVkeHUh?=
A2058	M4PtVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTJzLkS0O\|ch\|ryP	M2jncHNCVkeHUh?=
CHP-212	MonzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LxfWlEPTB;MkGuPVA2OSEQvF2=	MonvV2FPT0WU
KY821	M3uwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\2b2lEPTB;MkGuPVc2KM7:TR?=	NWW2NIxjW0GQR1XS
TYK-nu	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3n4WmlEPTB;MkKuNFY2OSEQvF2=	NG\oeYlUSU6JRWK=
JVM-2	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\6TY5rUUN3ME2yNk4zQTh\|IN88US=>	NEnBSGdUSU6JRWK=
KU812	M4HmbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTJ{LkezNVIh\|ryP	MULTRW5ITVJ?
MKN28	MlvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvVTWM2OD1{Mj65NFE2KM7:TR?=	NFXMOY5USU6JRWK=
ECC10	MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPmdZJKSzVyPUKzMlc1OSEQvF2=	M3jTdHNCVkeHUh?=
BHT-101	NF3NSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTJ2LkCwNFgh\|ryP	NH76RXhUSU6JRWK=
DU-4475	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rvZ2lEPTB;MkSuN\|M{PyEQvF2=	NFv4W3ZUSU6JRWK=
769-P	NEPRW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fnNmlEPTB;MkSuPFQ3PiEQvF2=	Mki4V2FPT0WU
HEC-1	NXfjfY9TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPmTWM2OD1{NT60OFUh\|ryP	M3PGfnNCVkeHUh?=
MOLT-13	NIr0[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILPRVJKSzVyPUK1MlU{OzFizszN	MljZV2FPT0WU
8505C	M1rFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTJ4LkS5O\|ch\|ryP	MUXTRW5ITVJ?
GB-1	MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTJ4LkexO\|Yh\|ryP	Mkn4V2FPT0WU
SF126	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TldGlEPTB;Mk[uO\|Y1QCEQvF2=	MknqV2FPT0WU
A4-Fuk	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfVSolXUUN3ME2yO{4yOjdzIN88US=>	NFvTVHBUSU6JRWK=
OVCAR-8	M3ywb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HqTmlEPTB;MkeuNVU{QSEQvF2=	Mmr2V2FPT0WU
NCI-H1304	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYS2XHFZUUN3ME2yO{42PCEQvF2=	MV7TRW5ITVJ?
GR-ST	M1:1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTtTWM2OD1{OD6wOFch\|ryP	M1zFW3NCVkeHUh?=
G-401	NVHZTGE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXKcm1KSzVyPUK4MlUxQTZizszN	NXf2enpSW0GQR1XS
LXF-289	NWXodJE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;PUmxKSzVyPUK4MlU3PTFizszN	M{DQS3NCVkeHUh?=
DBTRG-05MG	NVHVSY1bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDrO2NKSzVyPUK4MlkzODRizszN	M3jyVnNCVkeHUh?=
YKG-1	Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEi2cGlKSzVyPUK5Mlg3QCEQvF2=	MkL5V2FPT0WU
GAMG	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTJ7Lkm5N{DPxE1?	NX;TVnpsW0GQR1XS
HCT-116	M1\rTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTNyLkC1OFgh\|ryP	NGPWWotUSU6JRWK=
S-117	M2\IOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlnoTWM2OD1\|MT6yNlU4KM7:TR?=	NIPxPVdUSU6JRWK=
NCI-H1693	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjlXoNKSzVyPUOzMlY2PDJizszN	M{TNfnNCVkeHUh?=
A427	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fBdGlEPTB;M{OuPVk4PiEQvF2=	MV\TRW5ITVJ?
HT-29	M1\JbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1ywNWlEPTB;M{SuOlA{OiEQvF2=	M2fjWXNCVkeHUh?=
P12-ICHIKAWA	M3Xtd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7kTWM2OD1\|ND63OFkyKM7:TR?=	M4PT[HNCVkeHUh?=
CAL-51	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXGc3FrUUN3ME2zOU4xPzB7IN88US=>	MmHVV2FPT0WU
Ramos-2G6-4C10	M13vTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\lVZlKSzVyPUO1MlI1OjVizszN	MVPTRW5ITVJ?
SCH	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TKV2lEPTB;M{[uOFE4PCEQvF2=	NGHjSJhUSU6JRWK=
SK-MEL-24	M1q4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrydWtKSzVyPUO2MlkxPDRizszN	NUKyVnpPW0GQR1XS
SW1573	M3fQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEO4dlBKSzVyPUO4MlczOTZizszN	NFjEXXdUSU6JRWK=
BALL-1	NVniZ2dmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTN7LkKxNlkh\|ryP	M4i5b3NCVkeHUh?=
BE-13	MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XTOWlEPTB;M{muN\|I6KM7:TR?=	NVfUeGpLW0GQR1XS
GI-1	Mk\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIK5So1KSzVyPUO5Mlg3PDdizszN	NIW4eldUSU6JRWK=
GOTO	Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fxemlEPTB;M{muPVE{QSEQvF2=	Ml7BV2FPT0WU
A673	NY\3c41mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTqbHdnUUN3ME20NU4xOzR\|IN88US=>	MknPV2FPT0WU
KG-1	NFnOU\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTR\|LkO5OEDPxE1?	NYTyemN2W0GQR1XS
GP5d	NVfFTJdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LJ[2lEPTB;NESuNFY3PiEQvF2=	NIfPfmpUSU6JRWK=
MFM-223	Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mki5TWM2OD12ND6xNlI5KM7:TR?=	M2XRVnNCVkeHUh?=
OAW-42	NVHaOpl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkWxTWM2OD12ND6yOlQ{KM7:TR?=	NVXxfmpMW0GQR1XS
C8166	NGq0ZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLjTWM2OD12NT6wPFIzKM7:TR?=	NI\QOpNUSU6JRWK=
LU-99A	NWqwcpJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLVdZVsUUN3ME20Ok4yOzJ{IN88US=>	MXXTRW5ITVJ?
NCI-H23	NF7G[ZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHG4VY1KSzVyPUS2MlE4QDVizszN	M3q4NnNCVkeHUh?=
HO-1-N-1	NIn1cmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX2yTJB2UUN3ME20O{4xQTl6IN88US=>	MnT3V2FPT0WU
A3-KAW	Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13P[2lEPTB;NEeuNVAxPyEQvF2=	M164VXNCVkeHUh?=
CGTH-W-1	M4HKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrRc3dNUUN3ME20O{42ODZ7IN88US=>	NX;BVmpYW0GQR1XS
DJM-1	Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWT4Z4RxUUN3ME20O{42PDF\|IN88US=>	Mkj2V2FPT0WU
A101D	MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTR5Lk[zOVch\|ryP	M1rLXXNCVkeHUh?=
BB30-HNC	NXnZZWtoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rNSWlEPTB;NEiuN\|A4OiEQvF2=	NFTUVFdUSU6JRWK=
T98G	M3PXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;DNVVPUUN3ME20PE41PjN\|IN88US=>	NIC4NWhUSU6JRWK=
NCI-H1573	M2WzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETNZY1KSzVyPUS5MlQ1PjJizszN	M1:4eHNCVkeHUh?=
MEG-01	NEftVHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTR7Lke0NVEh\|ryP	NH3kc3NUSU6JRWK=
WM-115	NEX3bJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTR7LkmyNlIh\|ryP	NEPjSWJUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western Blot	DR5/CHOP; PubMed: 25531448 PLoS One (A) U87 GBM cells were treated with Olaparib (10 µM) for the indicated time points, subjected to immunoblotting and analyzed for the expression of DR5. B-D) U87 (B), U373 (C) and LN229 GBM cells (D) were treated with increasing concentrations of Olaparib (µM) for 7 hours, subjected to immunoblotting and analyzed for the expression of CHOP and DR5. E–F) MDA-MB-468 (E) and MDA-MB-436 (F) were treated with increasing concentrations (µM) of Olaparib for 7 hours, harvested for immunoblotting and analyzed for the expression of DR5. γH2AX/H2AX; PubMed: 22933245 EMBO Mol Med FK866 exacerbates levels of γH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and γH2AX. pATM; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 53BP1; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. NF-kB; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. pS6/S6; PubMed: 24831086 Oncotarget HCC1937 cells (BRCA1-inactive) were treated with 10 nM olaparib with indicated times. Whole-cell lysates were prepared and analyzed by Western blotting with the indicated antibodies.	25531448 22933245 27686740 24831086
Immunofluorescence	DNA damage; PubMed: 27686740 Cell Cycle (A) A comet assay and (B) γH2AX immunofluorescence assay were performed 72 h after olaparib treatment to identify DNA damage. A relatively higher level of DNA damage was observed in HN9-cisR cells; however, olaparib also induced slight DNA damage in olaparib-resistant HN4-cisR cells. Magnification: × 100 (comet assay); × 400 (γH2AX). γH2AX; PubMed: 28069876 Mol Cancer Ther Representative images of immunofluorescence (IF) staining for γH2AX in 22RV1 cells treated with of BI2536 (5 nM), Olaparib (10 µM) or both for 24 h. 22RV1 cells (1 × 105) were plated in 6-well plates on day 0 and then treated with BI2536, Olaparib or both for 24 h.	27686740 28069876
Growth inhibition assay	Cell viability ; PubMed: 25531448 PLoS One A-D): U87 (A), U373 (B), LN229 (C) and MDA-MB-468 (D) cells were treated with suboptimal dosages of TRAIL (A: 100 ng/ml, B: 25 ng/ml, C: TRAIL 200 ng/ml, D: 10 ng/ml), Olaparib (A–C: 10 µM, D: 5 µM) or the combination of both reagents for 48 hours. Thereafter, MTT assays were performed to determine cellular viability.	25531448
ELISA	IL-8; PubMed: 28456021 Virology ELISA measuring PAR levels in Akata-EBV cells. Cells were treated with 2.5 μM olaparib for 24 h to inhibit PARP activity. Data are shown as pg of PAR per μg of protein. GLP-1; PubMed: 29392078 Aging Dis Olaparib enhances promotes GLP-1 secretion in NCI-H716 cells Cells were stimulated for 30 minutes with or without 16 mM glucose. GLP-1 was measured by ELISA. Bars represent the mean of three independent experiments normalized to the control. Error bars indicate standard deviation. Statistical analyses were performed by two-tailed Student’s t-test and significance is denoted by asterisks where *P<0.05.	28456021 29392078

In vivo

Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. ^[1] Olaparib shows great response to Brca1^-/-;p53^-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad^-/-;p53^-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. ^[3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse FlashPlate assay (96-well screening assay): To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl₂,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD⁺ final assay concentration, and 0.075 μCi ³H-NAD⁺ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research: ^[1]	- Collapse Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D Concentrations: 1-300 nM Incubation Time: 7-14 days Method: The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: Brca1^-/-;p53^-/- mammary tumors are generated in K14cre;Brca1^F/F;p53^F/F mice. Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS Dosages: 50 mg/kg Administration: Administered via i.p. injection at 10 μL/g of body weight (Only for Reference)

References

[4] Weston VJ, et al, Blood, 2010, 116(22), 4578-4587.

- Collapse

Solubility (25°C)

In vitro	DMSO	86 mg/mL warmed (197.94 mM)
	Water	0.002 mg/mL (0.0 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Olaparib (AZD2281) SDF

Molecular Weight	434.46
Formula	C₂₄H₂₃FN₄O₃
CAS No.	763113-22-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	Ku-0059436
Smiles	FC1=C(C=C(CC2=NNC(=O)C3=C2C=CC=C3)C=C1)C(=O)N4CCN(CC4)C(=O)C5CC5

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04024254	Not yet recruiting	Drug: Folic Acid Tablet	Ovarian Cancer\|Breast Cancer\|Folic Acid Deficiency	Rush University Medical Center	August 2019	Phase 2\|Phase 3
NCT04005690	Recruiting	Drug: Cobimetinib\|Drug: Olaparib	Resectable Pancreatic Ductal Adenocarcinoma\|Stage 0 Pancreatic Cancer AJCC v8\|Stage I Pancreatic Cancer AJCC v8\|Stage IA Pancreatic Cancer AJCC v8\|Stage IB Pancreatic Cancer AJCC v8\|Stage II Pancreatic Cancer AJCC v8\|Stage IIA Pancreatic Cancer AJCC v8\|Stage IIB Pancreatic Cancer AJCC v8\|Stage III Pancreatic Cancer AJCC v8	OHSU Knight Cancer Institute\|National Cancer Institute (NCI)	August 1 2019	Phase 2
NCT03786796	Recruiting	Drug: Olaparib	Renal Cell Carcinoma\|Metastatic Renal Cell Carcinoma\|Kidney Cancer\|Renal Carcinoma\|Kidney Cancer Metastatic	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|AstraZeneca	June 3 2019	Phase 2
NCT03745950	Not yet recruiting	Drug: Olaparib Oral Capsule\|Drug: Placebo oral capsule	Endometrial Carcinoma	ARCAGY/ GINECO GROUP	February 1 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to prepare the solution of the compound (S1060) for in vivo study?
Answer:
We recommend the following formulation: 4% DMSO+30% PEG300+ 66%H2O. It is a clear solution and can be used for IP injection.
Question 2:
I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?
Answer:
For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.
Question 3:
How long can the chemical compound be stable in DMEM at 4 °C?
Answer:
The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Selective PARP Inhibitors

AG-14361 : PARP1-selective, K_i<5 nM.
Selective PARP Inhibitors

UPF 1069 : PARP2-selective, IC50=0.3 μM.
Most Potent PARP Inhibitor

MK-4827 (Niraparib) : PARP1, IC50=3.8 nM; PARP2, IC50=2.1 nM.
PARP Inhibitor in Clinical Trial

Iniparib (BSI-201) : Phase III for solid tumors.
Newest PARP Inhibitor

BMN 673 : Novel PARP inhibitor with IC50 of 0.58 nM. Also a potent inhibitor of PARP-2, but does not inhibit PARG and highly sensitive to PTEN mutation.

Related PARP Products

G007-LK ^New

G007-LK is a potent and selective tankyrase inhibitor with IC50 of 46 nM and 25 nM for TNKS1/2, respectively.
NU1025 ^New

NU1025 is a potent PARP inhibitor with IC50 of 400 nM.
SCR7 ^New

SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
Veliparib (ABT-888)

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with K_i of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

Features:Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Rucaparib (AG-014699) phosphate

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with K_i of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

Features:The first PARP inhibitor used in clinical trials combined with temozolomide.
Talazoparib (BMN 673)

Talazoparib (BMN 673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

Features:Most potent and selective PARPi reported thus far.
Iniparib (BSI-201)

Iniparib (BSI-201) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). Phase 3.
PJ34 HCl

PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.

Features:Water-soluble PARP1/2 inhibitor with >10,000-fold potentcy vs. 3-aminobenzamide (prototypical PARP inhibitor). Potential uses in cardiovascular diseases (stroke, cerebral ischemia, & myocardial ischemia).
AG-14361

AG14361 is a potent inhibitor of PARP1 with K_i of <5 nM in a cell-free assay. It is at least 1000-fold more potent than the benzamides.

Features:The 1st high-potency PARP-1 inhibitor with the specificity & in vivo activity to enhance chemotherapy and radiation therapy of human cancers.
A-966492

A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with K_i of 1 nM and 1.5 nM, respectively.

Features:A promising, structurally diverse benzimidazole analogue that is being further characterized preclinically.

Choose Your Country or Region

By Signaling Pathways

By product type

Olaparib (AZD2281)